企業プロフィール · Healthcare

Boston Scientific Corp

BSX · 米国株
取引所
米国株
国 / 地域
USA
上場日
1992年5月18日
従業員数
59,000
現在値
$45.29
リアルタイム · 2026年6月18日
ベイリー成長スコア
46/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 $45.29 リアルタイム · 保守的レンジと妥当レンジの間

総合バリュエーションレンジ · 保守的 $31–$40 / 妥当 $50–$65 / 楽観的 $80–$95。$45.29 時点で 保守的レンジと妥当レンジの間。

レポート公開時 $57.78(2026年5月24日)

この銘柄のレポートはお使いの言語でまだありません。

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

時価総額$668.12億
売上高(TTM)$206.14億
EBITDA$55億
純利益率17.29%
ROE14.66%
PER (TTM)18.81
予想PER13.39
PEG0.54
EPS$2.39
52週レンジ$44.80 – $109.50
アナリスト目標株価$77.10
アナリスト評価4.6 / 5

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。